Subject(s)
Adalimumab , Behcet Syndrome , Hidradenitis , Humans , Adalimumab/therapeutic use , Adalimumab/adverse effects , Behcet Syndrome/drug therapy , Behcet Syndrome/diagnosis , Behcet Syndrome/complications , Hidradenitis/chemically induced , Hidradenitis/drug therapy , Hidradenitis/pathology , Male , Anti-Inflammatory Agents/therapeutic use , Adult , Female , Neutrophils/pathologySubject(s)
Humans , Female , Middle Aged , Telangiectasis/etiology , Breast Neoplasms/drug therapy , Drug Eruptions/etiology , Trastuzumab/adverse effects , Antineoplastic Agents, Immunological/adverse effects , Telangiectasis/pathology , Breast Neoplasms/chemistry , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Drug Eruptions/pathology , Receptor, ErbB-2 , Trastuzumab/therapeutic use , Antineoplastic Agents, Immunological/therapeutic use , Maytansine/analogs & derivatives , Maytansine/adverse effects , Maytansine/therapeutic use , Neoplasm StagingSubject(s)
Antineoplastic Agents, Immunological/adverse effects , Breast Neoplasms/drug therapy , Drug Eruptions/etiology , Maytansine/analogs & derivatives , Telangiectasis/etiology , Trastuzumab/adverse effects , Ado-Trastuzumab Emtansine , Antineoplastic Agents, Immunological/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/chemistry , Drug Eruptions/pathology , Female , Humans , Maytansine/adverse effects , Maytansine/therapeutic use , Middle Aged , Neoplasm Staging , Receptor, ErbB-2 , Telangiectasis/pathology , Trastuzumab/therapeutic useABSTRACT
No disponible
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Aged, 80 and over , Urticaria/diagnosis , Purpura/diagnosis , Vasculitis, Leukocytoclastic, Cutaneous/diagnosis , BiopsyABSTRACT
No disponible
Subject(s)
Humans , Male , Middle Aged , Granuloma Annulare/complications , Granuloma Annulare/drug therapy , Granuloma Annulare , Adrenal Cortex Hormones/administration & dosage , Leukocytosis/diagnosis , Leukocytosis/drug therapy , Eosinophilia/diagnosis , Administration, Topical , Fluorescent Antibody Technique, Direct/methods , Complement C3/analysis , Antibodies, Antinuclear/analysis , Prednisone/administration & dosageSubject(s)
Acitretin/therapeutic use , Carcinoma, Basal Cell/diagnosis , Hypotrichosis/diagnosis , Keratolytic Agents/therapeutic use , Lymphoma, Follicular/diagnosis , Skin Neoplasms/diagnosis , Acitretin/administration & dosage , Carcinoma, Basal Cell/complications , Carcinoma, Basal Cell/drug therapy , Carcinoma, Basal Cell/pathology , Diagnosis, Differential , Female , Foot , Hand , Humans , Hypotrichosis/complications , Hypotrichosis/drug therapy , Hypotrichosis/pathology , Keratolytic Agents/administration & dosage , Lymphoma, Follicular/complications , Lymphoma, Follicular/drug therapy , Lymphoma, Follicular/pathology , Middle Aged , Skin Neoplasms/complications , Skin Neoplasms/drug therapy , Skin Neoplasms/pathologySubject(s)
Churg-Strauss Syndrome/complications , Granuloma Annulare/etiology , Scalp Dermatoses/etiology , Churg-Strauss Syndrome/diagnosis , Churg-Strauss Syndrome/pathology , Collagen/analysis , Giant Cells/pathology , Granuloma Annulare/pathology , Histiocytes/pathology , Humans , Male , Middle Aged , Recurrence , Scalp Dermatoses/pathologyABSTRACT
Nuclear 3'-end-polyadenylation is essential for the transport, stability and translation of virtually all eukaryotic mRNAs. Poly(A) tail extension can also occur in the cytoplasm, but the transcripts involved are incompletely understood, particularly in cancer. Here we identify a lineage-specific requirement of the cytoplasmic polyadenylation binding protein 4 (CPEB4) in malignant melanoma. CPEB4 is upregulated early in melanoma progression, as defined by computational and histological analyses. Melanoma cells are distinct from other tumour cell types in their dependency on CPEB4, not only to prevent mitotic aberrations, but to progress through G1/S cell cycle checkpoints. RNA immunoprecipitation, sequencing of bound transcripts and poly(A) length tests link the melanoma-specific functions of CPEB4 to signalling hubs specifically enriched in this disease. Essential in these CPEB4-controlled networks are the melanoma drivers MITF and RAB7A, a feature validated in clinical biopsies. These results provide new mechanistic links between cytoplasmic polyadenylation and lineage specification in melanoma.
Subject(s)
Melanoma/metabolism , RNA-Binding Proteins/metabolism , Animals , Cell Cycle , Cell Line, Tumor , Gene Expression Regulation, Neoplastic , Gene Silencing , Humans , Melanoma/genetics , Mice , Neoplasms, Experimental , RNA, Messenger/metabolism , RNA-Binding Proteins/geneticsABSTRACT
Both of these young patients presented with rashes that had spread from their abdomen to their arms and legs--but only on one side.
Subject(s)
Exanthema/diagnosis , Exanthema/drug therapy , Histamine Antagonists/administration & dosage , Pruritus/diagnosis , Pruritus/drug therapy , Administration, Oral , Adolescent , Child, Preschool , Female , Humans , Male , Pregnancy , Rare Diseases/diagnosis , Rare Diseases/drug therapy , Treatment OutcomeABSTRACT
Neuropathic ulcers in leprosy represent a therapeutic challenge for clinicians. Chronic ulcers affect patient health, emotional state and quality of life, causing considerable morbidity and mortality in addition to contributing to significant health care costs. The pathogenesis is mainly related to the abnormally increased pressure in areas such as the sole of the foot, secondary to lack of sensation and deformities induced by peripheral sensory-motor neuropathy. Conventional treatment of these wounds can be slow due to their chronic inflammatory state and the senescence of local reparative cells. Platelet-rich plasma (PRP) may restore the healing process, leading to a reparative phase. We present two patients with four neuropathic leprosy ulcers that have responded satisfactory to PRP treatment. PRP therapy has been growing as a viable treatment alternative for chronic ulcers. However, stronger scientific evidence is required to support its potential benefit for use in chronic wounds.
Subject(s)
Chronic Disease/drug therapy , Foot Ulcer/drug therapy , Leprosy/drug therapy , Peripheral Nervous System Diseases/drug therapy , Platelet-Rich Plasma , Wound Healing/physiology , Aged , Diabetic Neuropathies , Female , Foot Ulcer/diagnosis , Humans , Injections, Intralesional , Leprosy/diagnosis , Male , Peripheral Nervous System Diseases/diagnosis , Treatment OutcomeSubject(s)
Adrenergic beta-Antagonists/adverse effects , Dermatitis, Allergic Contact/etiology , Facial Dermatoses/chemically induced , Levobunolol/immunology , Timolol/adverse effects , Timolol/immunology , Adrenal Cortex Hormones/therapeutic use , Adrenergic beta-Antagonists/immunology , Cross Reactions , Dermatitis, Allergic Contact/drug therapy , Eyelids , Facial Dermatoses/drug therapy , Glaucoma/drug therapy , Humans , Male , Middle Aged , Ophthalmic SolutionsSubject(s)
Dermoscopy , Facial Neoplasms/pathology , Neoplasms, Basal Cell/pathology , Skin Neoplasms/pathology , Aged , Female , Humans , Lip Neoplasms/pathology , MaleSubject(s)
Dermoscopy , Eyelid Diseases/pathology , Lichen Sclerosus et Atrophicus/pathology , Child , Child, Preschool , HumansABSTRACT
No disponible
